- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04087720
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
June 30, 2022 updated by: Horizon Therapeutics Ireland DAC
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients With Uncontrolled Gout Who Have Undergone Kidney Transplantation
The primary objective of this study is to evaluate the effect of pegloticase on the response rate of sustained serum uric acid (sUA) reduction to sUA < 6 mg/dL during Month 6 of treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study design includes: 1) a Screening Period, lasting up to 35 days; 2) a 24-week treatment period which includes an End-of-Study (Week 24) /Early Termination Visit; 3) a safety follow-up phone/email Visit 30 days after the last infusion; and 4) a 3 month post-treatment follow up visit.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama Birmingham
-
Huntsville, Alabama, United States, 35805
- Nephrology Consultants
-
-
California
-
Los Angeles, California, United States, 90033
- Keck School of Medicine of USC
-
Northridge, California, United States, 91324
- Amicis Research Center
-
-
Florida
-
Tampa, Florida, United States, 33614
- Genesis Clinical Research
-
-
Georgia
-
Brunswick, Georgia, United States, 31520
- Coastal Medical Research
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Texas
-
Webster, Texas, United States, 77598
- Clear Lake Specialties
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to give informed consent;
- Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study;
- Adult men or women ≥ 18 years of age;
- Is a recipient of a de novo kidney from a living or deceased donor and is >1 year post transplant prior to screening;
- Is on a stable standard of care immunosuppression therapy for at least 3 months prior to screening;
- Kidney allograft is functional at entry, based on an estimated glomerular filtration rate (eGFR) ≥ 15 mL/min/1.73m²;
- Women of childbearing potential have a negative screening serum pregnancy test and will be required to use a medically approved form of birth control during their participation in the study;
Uncontrolled gout, defined as:
- Hyperuricemia during screening as documented by sUA ≥ 7 mg/dL during Screening and prior to entry into the Treatment Period (Note: the sUA may be repeated up to 3 times during the Screening Period to confirm eligibility), and
- Inability to maintain sUA <6 mg/dL on other urate-lowering therapy or intolerable side effects or contraindicated with conventional urate-lowering therapy, and
- At least 1 of the following:
i. Evidence of tophaceous deposits; ii. Recurrent gout flares defined as 2 or more flares in the 12 months prior to Screening; iii. Presence of chronic gouty arthritis;
- Able to tolerate low-dose prednisone (< 10 mg/day) as part of the required standard gout flare prophylaxis regimen for ≥ 1 week before the first infusion.
Exclusion Criteria:
- Any other organ transplant beside kidney;
- Any severe infection, unless treated and completely resolved at least 2 weeks prior to Day 1;
- Chronic or active hepatitis B virus infection;
- Known history of hepatitis C virus ribonucleic acid (RNA) positivity unless treated and viral load is negative;
- Known history of human immunodeficiency virus (HIV) positivity;
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency (tested at the Screening Visit);
- Decompensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (> 160/100 mm Hg) at the end of the Screening Period (Day 1 prior to infusion);
- Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not using an effective form of birth control, as determined by the Investigator;
- Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug;
- Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product;
- Receipt of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1, or plans to take an investigational drug during the study;
- Currently receiving systemic or radiologic treatment for ongoing cancer;
- History of malignancy within 5 years other than non-melanoma skin cancer, in situ carcinoma of cervix, early stage renal cell cancer or early stage prostate cancer that has been completely resected > 2 years prior to screening;
- Uncontrolled hyperglycemia with a plasma glucose value > 240 mg/dL at Screening that is not subsequently controlled by the end of the Screening Period;
- Diagnosis of osteomyelitis;
- Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome;
- Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study;
- Currently receiving allopurinol, febuxostat or other urate lowering medications and unable to discontinue medication 7 days prior to Day 1; or
- Currently receiving probenecid and unable to discontinue medication within 3 days, prior to Day 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pegloticase
Participants receive 8 mg pegloticase every 2 weeks from Day 1 through Week 22
|
intravenous (IV) infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6
Time Frame: Month 6 (Weeks 20, 21, 22, 23, 24)
|
sUA < 6 mg/dL responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 6, which includes pre-infusion and post-infusion results at Week 20, results at Week 21, pre-infusion and post-infusion results at Week 22, results at Week 23, results at Week 24, and unscheduled assessments of sUA collected between Week 20 and Week 24.
Two-sided Exact Clopper-Pearson confidence interval is used for the calculation of the 95% confidence interval.
|
Month 6 (Weeks 20, 21, 22, 23, 24)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of sUA < 5 mg/dL Responders During Month 6
Time Frame: Month 6 (Weeks 20, 21, 22, 23, and 24)
|
sUA < 5 mg/dL responders are defined as participants achieving and maintaining sUA <5 mg/dL for at least 80% of the time during Month 6, which includes pre-infusion and post-infusion results at Week 20, results at Week 21, pre-infusion and post-infusion results at Week 22, results at Week 23, results at Week 24, and unscheduled assessments of sUA collected between Week 20 and Week 24.
Two-sided Exact Clopper-Pearson confidence interval is used for the calculation of the 95% confidence interval.
|
Month 6 (Weeks 20, 21, 22, 23, and 24)
|
Change From Baseline in Health Assessment Questionnaire (HAQ) Pain Visual Analog Scale (VAS) Score Through Week 24
Time Frame: Baseline, Weeks 6, 14, 20, 24
|
The HAQ-Pain score consists of a doubly anchored, horizontal VAS 15 cm in length, and rates a participant's pain over the past week from 0 to 100 with 0 = no pain and 100 = severe pain.
Baseline is defined as the last measurement taken prior to the first infusion of pegloticase.
The 95% confidence interval is a two-sided normal theory-based 95% confidence interval.
|
Baseline, Weeks 6, 14, 20, 24
|
Change From Baseline in Heath Assessment Questionnaire - Disability Index (HAQ-DI) Score Through Week 24
Time Frame: Baseline, Weeks 6, 14, 20, 24
|
The HAQ-DI is a self-reported assessment of how a participant's illness affects their ability to function in their daily life over the past week.
The HAQ-DI for a participant is calculated as the mean of the following 8 category scores: Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities.
The HAQ-DI ranges from 0 to 3 with higher values indicating higher disability.
Baseline is defined as the last measurement taken prior to the first infusion of pegloticase.
The 95% confidence interval is a two-sided normal theory-based 95% confidence interval.
|
Baseline, Weeks 6, 14, 20, 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Colleen Canavan, BS, Horizon Therapeutics Ireland DAC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 9, 2019
Primary Completion (Actual)
July 6, 2021
Study Completion (Actual)
September 7, 2021
Study Registration Dates
First Submitted
September 11, 2019
First Submitted That Met QC Criteria
September 11, 2019
First Posted (Actual)
September 12, 2019
Study Record Updates
Last Update Posted (Actual)
July 26, 2022
Last Update Submitted That Met QC Criteria
June 30, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HZNP-KRY-406
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncontrolled Gout
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Horizon Therapeutics Ireland DACCompleted
-
Hadassah Medical OrganizationUnknownUncontrolled Type 1 Diabetic Patients
-
Alcon ResearchCompletedUncontrolled Intraocular PressureIndia
-
AstraZenecaNot yet recruiting
-
CVRx, Inc.Suspended
-
Verve Medical, IncClinical Accelerator (CRO); Israeli-Georgian Medical Research Clinic Helsicore and other collaboratorsActive, not recruitingHypertension | Uncontrolled HypertensionGeorgia
-
Abbott Medical DevicesCompletedUncontrolled HypertensionSpain, Belgium, Estonia, Italy, Portugal, United Kingdom
-
University of Illinois at Urbana-ChampaignNational Heart, Lung, and Blood Institute (NHLBI)UnknownCardiovascular Risk Factor | Uncontrolled HypertensionUnited States
Clinical Trials on Pegloticase
-
Savient PharmaceuticalsCompleted
-
Savient PharmaceuticalsCompletedChronic Kidney Disease Stage 5United States
-
Savient PharmaceuticalsCompletedGoutUnited States, Canada, Mexico
-
Horizon Pharma Rheumatology LLCCompletedRefractory Chronic GoutUnited States
-
Savient PharmaceuticalsCompletedChronic Gout Refractory to Conventional TherapyUnited States
-
University of Colorado, DenverRecruitingDiabetes Mellitus, Type 2 | Diabetes | Diabetes Complications | Type 2 Diabetes Mellitus | Diabetic Kidney Disease | Diabetic Nephropathies | Type2 Diabetes | HyperuricemiaUnited States
-
Selecta Biosciences, Inc.Completed
-
John SundySavient PharmaceuticalsCompleted
-
Ampel BioSolutions, LLCIND 2 Results LLCCompleted
-
University of Alabama at BirminghamUniversity of MichiganCompleted